Drug Trial Radar · NCT06720987
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Feb 4, 2025
Primary completion
Jun 30, 2029
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Kumquat Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198? * Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198. * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.
Conditions
- KRAS G12C Mutation
- KRAS G12S Mutation
- Solid Tumor Malignancies
- CRC (Colorectal Cancer)
- NSCLC
- NSCLC (Non-small-cell Lung Cancer)
- NSCLC Non-small Cell Lung Cancer
- Lung Cancer (Non-Small Cell)
- KRAS G12-mutant NSCLC
Interventions
KQB365Drug
Intravenous KQB365
CetuximabDrug
Intravenous cetuximab
KQB198Drug
Oral KQB198
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: From enrollment to the end of treatment
- Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: up to 35 months
- Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Part 2)Time frame: up to 35 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic, Phoenix
Phoenix, Arizona · Recruiting
Sarah Cannon Cancer Institute at HealthONE
Denver, Colorado · Recruiting
Mayo Clinic, Jacksonville
Jacksonville, Florida · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Mayo Clinic, Rochester
Rochester, Minnesota · Recruiting
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio · Recruiting
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Sydney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia, LLC
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.